Macrocycle Therapeutics to Treat Life-threatening Diseases

2021/06/30 by Gokhan Batur, Philipp Ermert, Johann Zimmermann +1
Biochemistry, Genetics and Molecular Biology · Chemistry · Medicine · #Cancer Treatment and Pharmacology #Cancer therapeutics and mechanisms #Click Chemistry and Applications

paper · pdf · doi:10.2533/chimia.2021.508

crossref issued 2021/06/30 · crossref published 2021/06/30 · crossref published-online 2021/06/30 · openalex publication_date 2021/06/30 · crossref created 2021/07/08 · crossref deposited 2022/09/21 · openalex created_date 2025/10/10 · openalex updated_date 2026/06/26 · crossref indexed 2026/07/28

Abstract

Polyphor's macrocycle platform led to the discovery of novel antibiotics addressing specifically Gramnegative bacteria by targeting outer membrane proteins. Furthermore, POL6014, an inhibitor of neutrophile elastase and balixafortide, a CXCR4 inhibitor have been discovered and developed from the platform. Currently a combination of balixafortide and eribulin is in Phase III clinical trial for the treatment of patients with advanced metastatic HER2-negative breast cancer.

Related

• Resistance of Gram-Negative Bacteria to Current Antibacterial Agents and Approaches to Resolve It
• Revolutionising Antibacterial Warfare: Machine Learning and Molecular Dynamics Unveiling Potential Gram-Negative Bacteria Inhibitors
• A novel antibiotic class targeting the lipopolysaccharide transporter
• Agents that increase the permeability of the outer membrane
• Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects